Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction

Abstract

Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's and Parkinson's diseases.

What is claimed is: 
     
         1 . A compound of general formula (Ic): 
       
         
           
           
               
               
           
         
         wherein 
         A is carbon (C) or nitrogen (N); 
         R 3  is hydrogen or heteroalkyl group; wherein when A is nitrogen (N), R 3  is absent; 
         Z is absent; 
         L 1  is —NH—; 
         Y 1  and Y 2  may be absent or present, but if present are independently a halogen; 
         or an enantiomer, diastereomer, mixture or salt thereof. 
       
     
     
         2 . The compound of  claim 1  having Formula 3: 
       
         
           
           
               
               
           
         
         or an enantiomer, diastereomer, mixture or salt thereof. 
       
     
     
         3 . A pharmaceutical composition containing the compound according to  claim 1  together with one or more pharmaceutically acceptable excipients. 
     
     
         4 . A method of making a medicament comprising formulating a compound according to  claim 1  with one or more pharmaceutically acceptable excipients. 
     
     
         5 . A method for treating a disease or disorder associated with enhanced apoptosis comprising administering to a subject in need thereof a therapeutically effective amount of the compound according to  claim 1 . 
     
     
         6 . A method for treating a disease or disorder selected from the list consisting of neurodegenerative diseases and disorders, cardiovascular diseases and disorders, Alzheimer's disease, Parkinson's disease, cardiac hypertrophy, heart failure, myocardial infarction, ischemia/reperfusion injury, apoptosis, autophagy of cardiac myocytes, atrial fibrillation (AF), and cardiac arrhythmia comprising administering to a subject in need thereof a therapeutically effective amount of the compound according to  claim 1 .